Next Article in Journal
A Comparative Study of Pathology and Host Immune Response Induced by Very Virulent Infectious Bursal Disease Virus in Experimentally Infected Chickens of Aseel and White Leghorn Breeds
Next Article in Special Issue
Mass Spectrometric Characterization of Narcolepsy-Associated Pandemic 2009 Influenza Vaccines
Previous Article in Journal
Identification and Isolation of Two Different Subpopulations Within African Swine Fever Virus Arm/07 Stock
Previous Article in Special Issue
Genetic Co-Administration of Soluble PD-1 Ectodomains Modifies Immune Responses against Influenza A Virus Induced by DNA Vaccination
Open AccessArticle

Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness

1
National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan
2
Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 300044, Taiwan
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 626; https://doi.org/10.3390/vaccines8040626
Received: 19 August 2020 / Revised: 11 October 2020 / Accepted: 16 October 2020 / Published: 25 October 2020
(This article belongs to the Special Issue Influenza Virus and Vaccine Development)
The embryonated egg-based platform currently produces the majority of seasonal influenza vaccines by employing a well-developed master donor virus (MDV, A/PR/8/34 (PR8)) to generate high-growth reassortants (HGRs) for A/H1N1 and A/H3N2 subtypes. Although the egg-based platform can supply enough seasonal influenza vaccines, it cannot meet surging demands during influenza pandemics. Therefore, multi-purpose platforms are desirable for pandemic preparedness. The Vero cell-based production platform is widely used for human vaccines and could be a potential multi-purpose platform for pandemic influenza vaccines. However, many wild-type and egg-derived influenza viruses cannot grow efficiently in Vero cells. Therefore, it is critical to develop Vero cell-derived high-growth MDVs for pandemic preparedness. In this study, we evaluated two in-house MDVs (Vero-15 and VB5) and two external MDVs (PR8 and PR8-HY) to generate Vero cell-derived HGRs for five avian influenza viruses (AIVs) with pandemic potentials (H5N1 clade 2.3.4, H5N1 clade 2.3.2.1, American-lineage H5N2, H7N9 first wave and H7N9 fifth wave). Overall, no single MDV could generate HGRs for all five AIVs, but this goal could be achieved by employing two in-house MDVs (vB5 and Vero-15). In immunization studies, mice received two doses of Vero cell-derived inactivated H5N1 and H7N9 whole virus antigens adjuvanted with alum and developed robust antibody responses. View Full-Text
Keywords: pandemic preparedness; Vero cell-derived influenza vaccine; master donor virus pandemic preparedness; Vero cell-derived influenza vaccine; master donor virus
Show Figures

Figure 1

MDPI and ACS Style

Chen, P.-L.; Tzeng, T.-T.; Hu, A.Y.-C.; Wang, L.H.-C.; Lee, M.-S. Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness. Vaccines 2020, 8, 626. https://doi.org/10.3390/vaccines8040626

AMA Style

Chen P-L, Tzeng T-T, Hu AY-C, Wang LH-C, Lee M-S. Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness. Vaccines. 2020; 8(4):626. https://doi.org/10.3390/vaccines8040626

Chicago/Turabian Style

Chen, Po-Ling; Tzeng, Tsai-Teng; Hu, Alan Y.-C.; Wang, Lily H.-C.; Lee, Min-Shi. 2020. "Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness" Vaccines 8, no. 4: 626. https://doi.org/10.3390/vaccines8040626

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop